Calidi Biotherapeutics, Inc. (CLDI)
NYSEAMERICAN: CLDI · Real-Time Price · USD
0.6500
-0.0450 (-6.47%)
At close: Mar 28, 2025, 4:00 PM
0.6200
-0.0300 (-4.62%)
After-hours: Mar 28, 2025, 7:53 PM EST

Company Description

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States.

Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.

The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.

Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics logo
Country United States
Founded 2014
Industry Biotechnology
Sector Healthcare
Employees 41
CEO Allan Camaisa

Contact Details

Address:
4475 Executive Drive, Suite 200
San Diego, California 92121
United States
Phone 858 794 9600
Website calidibio.com

Stock Details

Ticker Symbol CLDI
Exchange NYSEAMERICAN
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001855485
CUSIP Number 320703309
ISIN Number US3207033099
Employer ID 86-2967193
SIC Code 2836

Key Executives

Name Position
Allan J. Camaisa Chief Executive Officer and Chairman of the Board
Wendy Pizarro Campbell Esq. Chief Legal, Chief Corporate Dev, Chief Diversity and Corp Secretary and Director
Dr. Boris Minev M.D., Ph.D. President of Medical and Scientific Affairs and Interim Chief Medical Officer
Andrew C. Jackson Chief Financial Officer
Dr. Antonio Fernandez Santidrian Ph.D., Pharm.D. Head of Technical Operations and Chief Scientific Officer

Latest SEC Filings

Date Type Title
Mar 10, 2025 8-K Current Report
Feb 10, 2025 8-K/A [Amend] Current report
Feb 7, 2025 EFFECT Notice of Effectiveness
Feb 5, 2025 424B5 Filing
Feb 5, 2025 8-K Current Report
Jan 28, 2025 8-K Current Report
Jan 15, 2025 UPLOAD Filing
Jan 10, 2025 S-3 Registration statement under Securities Act of 1933
Jan 10, 2025 8-K Current Report
Jan 10, 2025 8-K Current Report